Insulet Corporation (PODD) SEC Filings & Earnings Calls

Increased leverage from upsized revolver, though undrawn at closing.

“aggregate amount of revolving credit commitments under the Credit Agreement is $750 million (the “Revolving Credit Facility”), which commitments were undrawn as of such date.” · word for word

Board departures may reduce institutional knowledge and governance continuity.

“stepped down from the Board for health reasons ... to focus on his candidacy for Governor of Massachusetts”

U.S. Omnipod growth guidance cut from 20-22% to 17-19% for FY2026, indicating potential type 2 scaling challenges

“FY 2026 Prior Guidance (as of 5/6/2026): U.S. Omnipod 20% - 22%; FY 2026 Guidance (as of 8/5/2026): U.S. Omnipod 17% - 19%”

Medical Device Correction Costs

“During the three and six months ended June 30, 2026, we recorded a net charge associated with the MDCs of $29.3 million and $41.0 million, respectively.” · word for word

Tariff Exposure

“We do not expect tariffs to have a significant impact on our gross margin in 2026; however, the elimination of the current exemption for certain medical devices would have a material impact on our results of operations in future years.” · word for word

Drug Delivery Revenue Decline

“Drug Delivery revenue was $5.8 million and $10.2 million for the three months ended June 30, 2026 and 2025, respectively.” · word for word

Product quality risk from manufacturing defect causing potential insulin under-delivery and serious adverse events.

“small tear in the tubing (cannula) just above the skin... insulin may leak... potentially leading to under-delivery of insulin” · word for word

Regulatory and litigation risk from voluntary correction and potential FDA scrutiny.

“future actions by the FDA and other regulatory bodies... could subject the Company to disputes, claims or proceedings” · word for word

Financial risk from up to $50M cost in 2026, though excluded from adjusted results.

“expects to incur up to $50 million of costs associated with this correction in 2026” · word for word

Drug Delivery revenue decline guided at ~50% for FY2026, indicating ongoing contraction in non-core segment

“Drug Delivery revenue of $3.3M; FY2026 guidance: Drug Delivery ~(50)%”

International revenue growth (59.4%) may face FX headwinds; constant currency growth lower at 45.2%

“International Omnipod revenue increased 59.4%, or 45.2% in constant currency”

Voluntary medical device correction

“We estimate the voluntary medical device correction and related costs will be approximately $30 million, more than half of which we expect to incur in 2026, with the remainder expected to be incurred in 2027.” · word for word

Tariff risk on medical devices

“the elimination of the current exemption for certain medical devices would have a material impact on our results of operations in future years.” · word for word

Concentration of manufacturing

“the concentration of manufacturing operations and storage of inventory in a limited number of locations” · word for word

Product recall/correction with serious adverse events; potential regulatory and litigation risk.

“Voluntary Medical Device Correction; 29 confirmed Serious Adverse Events; FDA involvement.”

CEO and CFO transition risk

“CEO and CFO transitions occurred in 2025; new CEO and CFO appointed.”

Debt extinguishment and investment losses

“Loss on extinguishment of debt $123.9M; loss on investments $7.5M.”

Product quality defect leading to serious adverse events; potential regulatory enforcement, litigation, and brand damage.

“18 reports of serious adverse events including hospitalization and DKA; FDA notified.”

No material risk; severance terms are standard and previously disclosed.

“Severance Agreement includes standard provisions; does not modify previously disclosed arrangements in any material respect.”

Tariff Exposure on Medical Devices

“Should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years.” · word for word

Supply Chain Concentration in China

“Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our products.” · word for word

Dependence on Third-Party Suppliers

“We have also seen significant price increases for various components and raw materials, including for semiconductor chips.” · word for word

Dependence on single supplier for key components; contract terms partially redacted.

“Confidential portions omitted; single-source supplier risk.”

No new risks; prior material weakness remediated.

“Material weakness remediated per Item 9A of FY2024 10-K.”

Tariff risk on medical devices

“should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years.” · word for word

Drug Delivery revenue decline expected.

“Drug Delivery guidance for FY 2025: (15)% - (10)% decline.”